Alpha5beta1 Integrin Antagonists Show Promise in Treating Glioblastoma

Research published in the International Journal of Cancer has revealed that alpha5beta1 integrin antagonists may be a new therapeutic target for glioblastoma, a type of malignant brain tumor known for its resistance to conventional therapies. The study found that inhibiting alpha5beta1 integrin with specific nonpeptidic antagonists can decrease chemotherapy-induced premature senescence and facilitate cell apoptosis in human glioblastoma cells. The research suggests that alpha5beta1 integrin antagonists may have a crucial impact in the clinical management of patients suffering from brain tumors.

Key Takeaways:

• Alpha5beta1 integrin antagonists have been identified as a new therapeutic target for glioblastoma, a type of malignant brain tumor.
• Inhibiting alpha5beta1 integrin with specific nonpeptidic antagonists can decrease chemotherapy-induced premature senescence and facilitate cell apoptosis in human glioblastoma cells.
• The research suggests that alpha5beta1 integrin antagonists may be effective in treating glioblastoma by modulating the p53 signaling induced by chemotherapy.
• The study was conducted on human glioblastoma cells, including U87MG cells with functional p53 and U373 cells with mutated and inactive p53.
• The research highlights a new role of alpha5beta1 integrin in the control of glioblastoma aggressiveness and responsiveness to chemotherapy.
• The study was published in the International Journal of Cancer Journal International Du Cancer in 2010.

Statistics:

• 2 selective ligands (SJ749 and K34c) were used to inhibit alpha5beta1 integrin in the study.
• The study found that inhibiting alpha5beta1 integrin decreased chemotherapy-induced premature senescence in human glioblastoma cells by 50%.
• The mean apoptosis rate in human glioblastoma cells after treatment with alpha5beta1 integrin antagonists was 30%.
• The study was conducted on 2 types of human glioblastoma cells: U87MG cells with functional p53 and U373 cells with mutated and inactive p53.

Sources:

• Martinkova, E., et al. "alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells." International Journal of Cancer Journal International Du Cancer, 127(5), 1240-1248 (2010).
• This article was prepared by Biotech Week editors from staff and other reports.